Oncology

Latest News

Oncology Drug Exkivity to be Voluntarily Withdrawn From US Market
Oncology Drug Exkivity to be Voluntarily Withdrawn From US Market

October 3rd 2023

Exkivity remains available while Takeda works with the FDA on withdrawal timing, and the company said that patients currently taking the therapy will continue to have access after it is withdrawn.

Bosutinib Approved by FDA for Pediatric Chronic Myelogenous Leukemia
Bosutinib Approved by FDA for Pediatric Chronic Myelogenous Leukemia

September 28th 2023

Cancer Rates Among People Living With HIV Have Declined, But More Research Still Needed
Cancer Rates Among People Living With HIV Have Declined, But More Research Still Needed

September 22nd 2023

Race, Ethnicity Data in Screening Model Could Reduce Lung Cancer Screening Disparities
Race, Ethnicity Data in Screening Model Could Reduce Lung Cancer Screening Disparities

September 21st 2023

TikTok Videos With Misinformation About Cancer Might be Hurting Women’s Health
TikTok Videos With Misinformation About Cancer Might be Hurting Women’s Health

September 21st 2023

Latest CME Events & Activities

ROS1-Targeted Treatments in NSCLC: Updates and Best Practices for Managed Care

1.5 Credit(s) / Oncology

View More

Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care

View More

Developing Clinical Pathways for Treatment of Advanced/Metastatic ccRCC in Managed Care Pharmacy: Opportunities, Challenges, and Best Practices

1.5 Credits / Oncology

View More

Investigating the Optimal Use of Novel Immunotherapies for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

1.5 / Oncology, Hematology

View More

Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer

1.5 Credits / Oncology, Women's Health

View More

Optimizing Care of Patients on Immune Checkpoint Inhibitors: An Oncology Primer for Community Pharmacists

1.25 Credits / Oncology

View More

Updates on the Utility of PARP Inhibitors in the Treatment of Ovarian Cancer: Opportunities for Pharmacists to Improve Patient Care

0.75 Credit / Oncology, Women's Health

View More

Oral Chemotherapy Parity Legislation: Opportunities for Cancer Care Equity

1.0 Credit / Law, Oncology

View More

Exploring the Evolving Treatment Landscape for Patients With Waldenström Macroglobulinemia

0.75 Credit / Oncology

View More

Advances in the Use of Immune Checkpoint Inhibitors to Treat Non-Melanoma Skin Cancers: Updates for Oncology Pharmacists

0.75 Credit / Oncology

View More

Acute Myeloid Leukemia: Novel Targeted Therapies and the Role of the Pharmacist

0.75 Credit / Oncology

View More

The Role of Immune Checkpoint Inhibitors in Cutaneous Melanoma: Evaluating Therapeutic Trends

0.75 Credit / Oncology

View More

Advances in Prostate Cancer: An Evidence-based Review for Managed Care Professionals

1.0 Credit / Oncology, Urology

View More

ESMO Congress 2022: Advances and Best Practices for Managed Care Pharmacists in the Treatment of Metastatic Head and Neck Squamous cell Carcinoma

1.0 Credit / Oncology

View More

Making the Most of Anti-Androgen Therapies in Prostate Cancer Through Pharmacist Interventions

1.25 Credits / Oncology

View More

Advances in High-Risk Myelodysplastic Syndromes: Insights and Application for Managed Care With ASH Annual Meeting Coverage

1.0 Credit / Hematology, Oncology

View More

A Pharmacist’s Guide to the Use of Targeted Therapy for HER2-Positive Breast Cancer

1.5 Credits / Oncology, Women's Health

View More

Managed Care Considerations and Implementation Strategies for Biosimilars in Oncology

1.0 Credit / Biosimilars, Oncology

View More

Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on Novel Immunotherapies

1.5 Credits / Hematology, Oncology

View More

Advances in the Treatment of Non-Melanoma Skin Cancers: The Role of Immune Checkpoint Inhibitors

1.5 Credits / Dermatology, Oncology

View More

Continuing the Conversation: Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on Novel Immunotherapies

0.5 Credit / Hematology, Oncology

View More

Exploring New and Emerging Oral Treatments in HR-Positive, HER2-Negative Breast Cancer: A Primer for Health-System Pharmacists

1.5 Credits / Breast Cancer, Oncology, Women's Health

View More

Tumor-Infiltrating Lymphocytes: Infiltrating the Boundaries of Cancer Care in Solid Tumors Through a Managed Care Lens

1.0 Credit / Oncology

View More

Updates in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease and the Role of the Oncology Pharmacist

1.5 Credits / Oncology

View More

Oncology Pharmacists Connect: Winter 2024

View More

Prostate Cancer: Insights and Application for Managed Care from ASCO 2022

1.0 Credit / Oncology, Urology

View More

Updates in the Targeted Treatment and Management of Unresectable or Metastatic Cholangiocarcinoma for Managed Care Pharmacists

1.0 Credit / Oncology, Rare Diseases

View More

Managed Care Insights on Optimizing the Use of BCMA-Targeted Treatments in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

The Evolving Treatment Landscape for HR+/HER2- Breast Cancer: Updates and Considerations for Managed Care

1.5 Credits / Oncology, Women's Health

View More

Exploring Clinical Updates in HR+/HER2- Breast Cancer Treatment and the Impact on Patient Care

1.0 Credit / Oncology, Women’s Health

View More

More News

© 2023 MJH Life Sciences

All rights reserved.